Maternal Serum α-Fetoprotein Levels during Pregnancy and Testicular Cancer in Male Offspring: A Cohort Study within a Danish Pregnancy Screening Registry.
pregnancy
serum
testicular cancer
α-fetoprotein
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
28 10 2022
28 10 2022
Historique:
received:
24
08
2022
revised:
26
10
2022
accepted:
26
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Testicular cancer is believed to originate from disruptions of normal androgen-estrogen balance in-utero. α-fetoprotein (AFP) may modify fetal response to estrogens via estrogen interaction. In a cohort study, we investigated the association between circulating maternal pregnancy AFP and testicular cancer risk in offspring. Of the 56,709 live-born males from a pregnancy screening registry in 1980-1995, our study included 50,519 singleton males with available second trimester blood samples from their mothers and complete covariate ascertainment. Testicular cancer diagnoses and covariate data were obtained from nationwide Danish health registries. Cox regression and Kaplan-Meier analyses estimated the prospective risk of testicular cancer (all, seminoma, nonseminoma) by AFP multiples of the median. During follow-up, 163 (0.3%) of the included males developed testicular cancer, of which 89 (54.6%) were nonseminomas. Maternal serum AFP levels greater than/equal to the median were associated with a relative risk of testicular cancer close to unity (RR 1.04, 95% CI 0.76; 1.41) compared to AFP below the median. Associations differed by type of testicular cancer (RR
Identifiants
pubmed: 36360990
pii: ijerph192114112
doi: 10.3390/ijerph192114112
pmc: PMC9655085
pii:
doi:
Substances chimiques
alpha-Fetoproteins
0
Estrogens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 1R01CA236816-01A1
Pays : United States
Références
Nat Rev Endocrinol. 2014 Sep;10(9):553-62
pubmed: 24935122
Fertil Steril. 2008 Feb;89(2 Suppl):e33-8
pubmed: 18308057
Hum Reprod. 2001 May;16(5):972-8
pubmed: 11331648
Andrology. 2015 Jan;3(1):4-12
pubmed: 25331326
Acta Radiol Oncol. 1984;23(4):239-47
pubmed: 6093440
Best Pract Res Clin Endocrinol Metab. 2006 Mar;20(1):77-90
pubmed: 16522521
Br Med J. 1975 Mar 22;1(5959):651-2
pubmed: 47778
Br J Cancer. 2005 May 9;92(9):1787-93
pubmed: 15841083
Cell Biol Int. 2004;28(12):913-33
pubmed: 15566961
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
Am J Mens Health. 2018 Sep;12(5):1774-1783
pubmed: 30008248
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Am J Epidemiol. 2006 Sep 1;164(5):478-86
pubmed: 16790515
Eur Urol. 2014 Dec;66(6):1172-8
pubmed: 25064686
Exp Biol Med (Maywood). 2004 Jun;229(6):439-63
pubmed: 15169963
Int J Epidemiol. 2010 Dec;39(6):1605-18
pubmed: 20660640
J Clin Invest. 1967 Jun;46(6):1010-6
pubmed: 6067376
BMC Cancer. 2020 Apr 6;20(1):284
pubmed: 32252689
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Cancer. 2018 Jul 1;124(13):2724-2732
pubmed: 29660851
Scand J Public Health. 2011 Jul;39(7 Suppl):42-5
pubmed: 21775350
Cancer Res. 1990 Jan 15;50(2):415-20
pubmed: 1688512
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Obstet Gynecol Surv. 2003 Dec;58(12):804-26
pubmed: 14668662
Future Oncol. 2009 Nov;5(9):1389-402
pubmed: 19903067
Biochim Biophys Acta. 1993 Sep 3;1202(1):135-42
pubmed: 7690596
Int J Androl. 2007 Aug;30(4):206-13; discussion 213-4
pubmed: 17708751
Ultrasound Obstet Gynecol. 2015 Jul;46(1):34-41
pubmed: 25652769
Andrologia. 2005 Dec;37(6):217-8
pubmed: 16336254
Int J Androl. 1987 Feb;10(1):19-28
pubmed: 3034791
Open Access J Urol. 2011 Dec 30;4:1-8
pubmed: 24198649